Publication date: Sep 10, 2025
“The safety profile of the vaccine was consistent with previous studies, with no new safety concerns identified. “In both age groups, 14 days following vaccination, LP. 8.1-neutralizing antibody titers exceeded pre-vaccination levels, on average, by at least 4-fold,” Pfizer said in a press release. Camosun College / Flickr ccYesterday Pfizer and BioNTech reported phase 3 clinical trial data for their updated COVID vaccine, Comirnaty.
| Concepts | Keywords |
|---|---|
| Ccyesterday | Adults |
| Fda | Clinical |
| Immunological | Condition |
| Seniors | Covid |
| Fda | |
| Fold | |
| Increase | |
| Neutralizing | |
| Older | |
| Pfizer | |
| Phase | |
| Safety | |
| Trial | |
| Underlying | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Release |
Original Article
(Visited 7 times, 1 visits today)